CTRI/2022/09/045166尚未招募3 期
An open label single arm study to evaluate the effect of Siddharthakavachadi Cream in Mukhadushika (Acne)
DR PRATHIBHA G0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Female patients aged between 10 and 50 years old.
- •2.Patients with clinical presentations of Acne
- •3.Those with grade1 to grade 5 Acne. (Assessed using Acne Global Severity Scale-FDA).
- •4.Those with mild to severe post acne scarring (Assessed using Global Scale for Acne Scar Severity [SCAR-S])
排除标准
- •1.Patients who are known cases of other skin pathologies.
- •2.History of taking the anti-acne treatment during the last 4 weeks.
- •3.Pregnant women
- •4.Lactating mothers
研究者
相似试验
招募中
3 期
A study to evaluate the effect of nethika Naturals Womens care suppliment in women with prolonged intermenstrual periodCTRI/2022/03/041049ethika Naturals Pvt Ltd
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-GBF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-SKF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisEUCTR2016-002937-31-BGF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple SclerosisEUCTR2016-002937-31-FRF. Hoffmann-La Roche Ltd600